Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Matching PlaceboDrug: IW-1701
- Registration Number
- NCT02572349
- Lead Sponsor
- Cyclerion Therapeutics
- Brief Summary
The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Matching Placebo for IW-1701 Matching Placebo Single Dose IW-1701 IW-1701 Single Dose
- Primary Outcome Measures
Name Time Method Assessment of the safety and tolerability of IW-1701 in healthy subjects via adverse events From baseline up to 8 days The primary objectives of this study are to assess the safety and tolerability of single ascending dosage levels of IW-1701 versus placebo in healthy subjects.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ironwood Investigational Site
🇺🇸San Antonio, Texas, United States